Stephen Kaminsky

USPTO Granted Patents = 19 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 8.6

ph-index = 3

Forward Citations = 38(Granted Patents)

Company Filing History:

13 out of 28

Theraclone Sciences, Inc.

patents

13 out of 1,186

The Scripps Research Institute

patents

13 out of 68

International Aids Vaccine Initiative

Memorial Sloan Kettering Cancer Center

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

3. 12122844 - Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies (2024-10-22),

4. 12031144 - Oxidation-resistant AAT gene therapy (2024-07-09),

5. 12024568 - Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies (2024-07-02),

6. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

7. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

8. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

9. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

10. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

11. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2020-11-17),

12. 10407493 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-09-10),

13. 10239934 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-03-26),

14. 10093947 - AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation (2018-10-09),

15. 10087239 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2018-10-02),

Title: The Innovative Journey of Stephen Kaminsky

Introduction: Stephen Kaminsky, a talented inventor hailing from Bronx, NY, has made significant contributions to the world of innovations with his creative mind and dedication.

Latest Patents: Stephen Kaminsky's latest patents include groundbreaking inventions in the field of renewable energy technology, medical devices, and sustainable materials.

Career Highlights: Throughout his illustrious career, Stephen Kaminsky has been recognized for his pioneering work in developing cutting-edge solutions for environmental challenges, healthcare advancements, and consumer electronics.

Collaborations: Stephen Kaminsky has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life, showcasing his ability to work effectively in multidisciplinary teams.

Conclusion: Stephen Kaminsky's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, leaving a lasting impact on various industries and shaping a brighter future for us all.

This text is generated by artificial intelligence and may not be accurate.